Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CyPep-1 + Pembrolizumab in advanced HNSCC, melanoma, and TNBC
NCT05383170Phase 2Completed
- Sponsor
- Cytovation
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Peptides
- Countries
- 5
01
Overview
A Phase 2 trial of cypep-1 in head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), sponsored by Cytovation. Started Mar 2023; status: completed.
02
Drugs
cypep-1
03
Conditions
head and neck squamous cell carcinoma (HNSCC)melanomatriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05383170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383170.